Biocorp launches Inspair inhaler monitoring add-on

Bespak metered-dose inhaler

French devicemaker Biocorp is launching its Inspair sensor, which is designed to connect to asthma and COPD inhalers and provide detailed information to patients and physicians regarding proper use of the device.

Biocorp specializes in data-wiring instruments like its internet-connected DataPen for recording insulin injection on a mobile app or add-ons that accomplish the same task with existing delivery devices. Inspair follows along those lines, adapting to most metered-dose inhalers to record data.

And asthma and COPD, even with the right inhaler, can be difficult to treat due to poor patient management and severe complications of the symptoms.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Inspair connects to the inhaler’s mouthpiece to record daily inhalation data, monitor correct preparation of the canister, detect incorrect dosing and give a patient steps for inhalation if needed. It does this through small sensors and an electronic card, as well as adapters to fit different mouthpieces.

“Biocorp’s objective is to develop innovative solutions in order to improve treatment compliance by patients suffering from chronic diseases,” Biocorp CEO Jacques Gardette said. “Significant applications have been developed in diabetology, endocrinology and neurology with the Datapen and Easylog devices, and our new sensor Inspair also positions us in the area of chronic lung diseases which affect an increasing number of people in need of new solutions to improve compliance.”


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.